Saxagliptin 2.5 mg (Generic)

Product Overview

Saxagliptin 2.5 mg is a generic formulation of a dipeptidyl peptidase‑4 (DPP‑4) inhibitor used in the management of type 2 diabetes mellitus. Manufactured by AstraZeneca Pharma India Ltd, the product is supplied in a strip containing 14 tablets, each delivering a precise 2.5 mg dose of the active ingredient. Pack size options include 28, 56, and 84 tablets, allowing patients and clinicians to select a quantity that matches treatment duration. The medication is marketed as a convenient oral therapy that helps lower blood glucose levels when diet and exercise alone are insufficient.

What is Saxagliptin 2.5 mg?

Saxagliptin 2.5 mg belongs to the class of DPP‑4 inhibitors, a group of antidiabetic agents that enhance the body’s natural incretin hormones. By blocking the DPP‑4 enzyme, saxagliptin prevents the breakdown of glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP), leading to increased insulin secretion and reduced glucagon release after meals. The 2.5 mg strength is the starting dose recommended for most adult patients with type 2 diabetes who have not previously used a DPP‑4 inhibitor. The tablet is film‑coated and intended to be taken whole, without crushing or chewing.

Uses and Benefits

The primary indication for saxagliptin 2.5 mg is to improve glycemic control in adults with type 2 diabetes mellitus. Clinical studies have demonstrated that the drug reduces fasting plasma glucose and post‑prandial glucose excursions, contributing to lower HbA1c values by approximately 0.5 % to 0.8 % when used as monotherapy or in combination with metformin, sulfonylureas, or insulin. Benefits include a low risk of hypoglycemia when used alone, once‑daily dosing that improves adherence, and a favorable safety profile with minimal weight gain. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), effective glucose management can reduce the risk of diabetes‑related complications.

How It Works

Saxagliptin exerts its antidiabetic effect by selectively inhibiting the enzyme dipeptidyl peptidase‑4 (DPP‑4). DPP‑4 normally cleaves incretin hormones such as GLP‑1 and GIP, which are released from the intestinal mucosa in response to nutrient intake. Inhibition of DPP‑4 prolongs the activity of these hormones, leading to enhanced glucose‑dependent insulin secretion from pancreatic β‑cells and suppression of glucagon release from α‑cells. The resulting increase in insulin and decrease in glucagon act together to lower blood glucose concentrations without causing excessive insulin release, thereby minimizing the risk of hypoglycemia.

Dosage Guidelines

The recommended initial dose of saxagliptin 2.5 mg is one tablet taken orally once daily, regardless of meals. In patients with moderate to severe renal impairment (estimated glomerular filtration rate <60 mL/min/1.73 m²), the dose may be reduced to 2.5 mg every other day, but this adjustment should only be made under the supervision of a qualified healthcare professional. The tablet should be swallowed whole with a full glass of water. If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular dosing schedule resumed. Consistency in timing helps maintain steady plasma concentrations of the drug. For more detailed prescribing information, see the FDA prescribing information.

Side Effects

Like all medications, saxagliptin 2.5 mg can cause adverse effects. The most commonly reported side effects include nasopharyngitis, headache, and urinary tract infections, which are usually mild and transient. Less frequent but clinically important adverse reactions may involve pancreatitis, severe joint pain, and hypersensitivity reactions such as rash or angioedema. Rarely, elevated liver enzymes have been observed, necessitating periodic monitoring of hepatic function in patients with pre‑existing liver disease. Patients should discontinue the medication and seek medical attention if they experience persistent vomiting, severe abdominal pain, or signs of an allergic reaction.

Warnings and Precautions

Before initiating therapy with saxagliptin 2.5 mg, clinicians should assess renal function, as the drug is primarily excreted unchanged through the kidneys. Caution is advised in patients with a history of pancreatitis, severe gastrointestinal disorders, or known hypersensitivity to the drug or its excipients. Concomitant use with strong CYP3A4 inhibitors or inducers may alter saxagliptin exposure and should be avoided unless clinically justified. Pregnant or breastfeeding women should only use the medication if the potential benefit outweighs the risk, and they must consult a healthcare provider. The product should be stored at room temperature, protected from moisture and heat, and kept out of reach of children. For additional safety data, refer to the MedlinePlus entry on saxagliptin.

Frequently Asked Questions

Can saxagliptin 2.5 mg be taken with other diabetes medications?

Yes, it can be combined with metformin, sulfonylureas, or insulin, but dosage adjustments may be needed to avoid hypoglycemia.

Is dose adjustment required in elderly patients?

Elderly patients do not require a lower dose solely based on age, but renal function should be evaluated, as kidney function often declines with age.

What should I do if I experience severe abdominal pain?

Discontinue the medication and seek immediate medical attention, as this could signal pancreatitis.

How long does it take to see improvement in blood sugar levels?

Glycemic control may begin within 1–2 weeks, but the full effect on HbA1c is typically observed after 12–24 weeks of consistent use.

Can the medication be crushed or split?

No, the tablet should be swallowed whole; crushing or splitting may alter the release profile and increase the risk of side effects.